98%
921
2 minutes
20
Background Cardiac involvement can be an initial manifestation in sarcoidosis. However, little is known about the association between various clinical phenotypes of cardiac sarcoidosis (CS) and outcomes. We aimed to analyze the relation of different clinical manifestations with outcomes of CS and to investigate the relative importance of clinical features influencing overall survival. Methods and Results A retrospective cohort of 141 patients with CS enrolled at 2 Swedish university hospitals was studied. Presentation, imaging studies, and outcomes of de novo CS and previously known extracardiac sarcoidosis were compared. Survival free of primary composite outcome (ventricular arrhythmias, heart transplantation, or death) was assessed. Machine learning algorithm was used to study the relative importance of clinical features in predicting outcome. Sixty-two patients with de novo CS and 79 with previously known extracardiac sarcoidosis were included. De novo CS showed more advanced New York Heart Association class (=0.02), higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) (<0.001), and troponins (<0.001), as well as a higher prevalence of right ventricular dysfunction (<0.001). During a median (interquartile range) follow-up of 61 (44-77) months, event-free survival was shorter in patients with de novo CS (<0.001). The top 5 features predicting worse event-free survival in order of importance were as follows: impaired tricuspid annular plane systolic excursion, de novo CS, reduced right ventricular ejection fraction, absence of β-blockers, and lower left ventricular ejection fraction. Conclusions Patients with de novo CS displayed more severe disease and worse outcomes compared with patients with previously known extracardiac sarcoidosis. Using machine learning, right ventricular dysfunction and de novo CS stand out as strong overall predictors of impaired survival.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492974 | PMC |
http://dx.doi.org/10.1161/JAHA.123.029481 | DOI Listing |
Indian Heart J
August 2025
Cardiothoracic Centre, All India Institute of Medical Sciences, New Delhi, India.
This retrospective observational study was conducted in a tertiary care hospital to assess the challenges involved in the diagnosis of cardiac sarcoidosis. The study included a total of 42 patients with primary cardiac manifestation of sarcoidosis and imaging evidence of patchy myocardial inflammation. Ventricular tachycardia(20) was the most common cardiac manifestation, followed by heart failure(12) and complete heart block(10).
View Article and Find Full Text PDFInt J Cardiol
August 2025
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Introduction: A clinical significance of extra-cardiac uptake of F-fluorodeoxyglucose positron emission tomography (F-FDG-PET), particularly in the brain, is unclear in cardiac sarcoidosis (CS).
Methods And Results: We analysed data from 84 CS patients (mean age 58.3 years, 70.
J Res Med Sci
July 2025
Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Background: Cardiac involvement in sarcoidosis is associated with high mortality but is often underrecognized due to diagnostic challenges. Advanced imaging modalities like Cardiac Magnetic Resonance (CMR) and Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) are highly sensitive for detecting myocardial inflammation and scarring, aiding in the diagnosis and management of cardiac sarcoidosis. The objective of this study was to characterize the imaging features of cardiac sarcoidosis in Iranian patients using these advanced cardiac imaging modalities.
View Article and Find Full Text PDFCJC Open
June 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Clinical characteristics of progressive heart failure warranting advanced heart failure (AHF) therapies are not well defined in patients with atypical cause-specific cardiomyopathies, as in conventional ischemic and dilated cardiomyopathies. Some of these specific cardiomyopathies are associated with systemic diseases, and the impact and the severity of extracardiac involvement is crucial in defining the appropriate choice of AHF therapies. This review focuses on special considerations in cause-specific cardiomyopathies, such as hypertrophic cardiomyopathy, cardiac sarcoidosis, cardiac amyloidosis, and arrhythmogenic right ventricular cardiomyopathy.
View Article and Find Full Text PDFCirc Arrhythm Electrophysiol
July 2025
Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond (A.T., J.D.L.R.M., K.A.E., J.K.).
Background: Differences in cardiac sarcoidosis between racial groups remain understudied. Therefore, this study aims to explore race differences in patients with cardiac sarcoidosis.
Methods: We analyzed data from the Cardiac Sarcoidosis Consortium, an international registry including over 25 centers.